Literature DB >> 21729239

Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A.

S Henrard1, N Speybroeck, C Hermans.   

Abstract

BACKGROUND: The treatment of hemophilia A requires infusions of factor VIII (FVIII) concentrates. The number of units to be given in order to obtain the target level is calculated using the formula: [body weight (BW) × desired FVIII increase]/2, which assumes that each unit infused per kg of BW increases the FVIII level by 2%.
OBJECTIVES: The present observational study evaluated the dependence of FVIII recovery on different morphometrical variables: BW, fat mass index (FMI), body mass index, and the difference between actual and ideal BW. PATIENTS AND METHODS: FVIII recovery was measured in 46 non-actively bleeding hemophilia A patients, being treated with a recombinant FVIII concentrate. Regression trees were used to identify morphometrical predictors of recovery.
RESULTS: The median recovery was 2.08 for all patients, 2.63 for those with a BW ≥ 81.0 kg and 1.87 for others (P < 0.001). The recovery was significantly higher when FMI was ≥ 20% compared with FMI < 15% (median recovery: 2.35 vs. 1.74; P = 0.007). Using regression trees, three groups were created: BW < 80.5 kg and FMI < 22.3%, BW < 80.5 kg and FMI ≥ 22.3% and BW ≥ 80.5 kg. Median recovery in these groups was 1.80, 2.16 and 2.63, respectively (P < 0.001).
CONCLUSIONS: The dose calculation of FVIII should take into account both BW and FMI, and be adapted to underweight or overweight patients. Comparison of the average recovery after different FVIII concentrates should keep in mind morphometrical patient characteristics.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21729239     DOI: 10.1111/j.1538-7836.2011.04431.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

1.  Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients.

Authors:  Séverine Henrard; Niko Speybroeck; Cedric Hermans
Journal:  Haematologica       Date:  2013-05-03       Impact factor: 9.941

Review 2.  Evidence-Based Minireview: For overweight or obese persons with hemophilia A, should factor VIII dosing be based on ideal or actual body weight?

Authors:  Nicoletta Machin; Ming Y Lim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A.

Authors:  Zhenping Chen; Kun Huang; Gang Li; Yingzi Zhen; Xinyi Wu; Ai Di; Guoqing Liu; Zekun Li; Iorio Alfonso; Runhui Wu
Journal:  Pediatr Investig       Date:  2021-03-22

4.  Lower physical activity and altered body composition in patients with haemophilia compared with healthy controls.

Authors:  Peter Putz; Meike Klinger; Christoph Male; Ingrid Pabinger
Journal:  Haemophilia       Date:  2021-02-12       Impact factor: 4.287

5.  Effects of short-term aerobic, resistance and combined exercises on the lipid profiles and quality of life in overweight individuals with moderate hemophilia A: A randomized controlled trial.

Authors:  Behrouz Parhampour; Mehdi Dadgoo; Giti Torkaman; Roya Ravanbod; Tina Delsouz Bahri; Mohammad Jazebi; Seyed Mehdi Mohsenipour; Behnoosh Vasaghi-Gharamaleki
Journal:  Med J Islam Repub Iran       Date:  2021-06-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.